Mechanism of action, clinical effectiveness, and optimal therapeutic range

被引：358

作者：

Hirsh, J ^{[1
]}

Dalen, JE ^{[1
]}

Anderson, DR ^{[1
]}

Poller, L ^{[1
]}

Bussey, H ^{[1
]}

Ansell, J ^{[1
]}

Deykin, D ^{[1
]}

Brandt, JT ^{[1
]}

机构：

[1] Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada

来源：

关键词：

D O I：

10.1378/chest.114.5_Supplement.445S

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页码：445S / 469S

页数：25

共 250 条

[1] Adcock DM, 1997, AM J CLIN PATHOL, V107, P105
[2] AGENO W, 1998, J THROMB THROMBOLY S, V5, pS69
[3] ATRIAL-FIBRILLATION AND STROKE - 3 NEW STUDIES, 3 REMAINING QUESTIONS
ALBERS, GW
[J]. ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (13) : 1443 - 1448
[4] STROKE PREVENTION IN NONVALVULAR ATRIAL-FIBRILLATION - A REVIEW OF PROSPECTIVE RANDOMIZED TRIALS
ALBERS, GW
SHERMAN, DG
GRESS, DR
PAULSETH, JE
PETERSEN, P
[J]. ANNALS OF NEUROLOGY, 1991, 30 (04) : 511 - 518
[5] ALTMAN R, 1991, J THORAC CARDIOV SUR, V101, P427
[6] HEREDITARY WARFARIN RESISTANCE - INVESTIGATION OF A RARE PHENOMENON
ALVING, BM
STRICKLER, MP
KNIGHT, RD
BARR, CF
BERENBERG, JL
PECK, CC
[J]. ARCHIVES OF INTERNAL MEDICINE, 1985, 145 (03) : 499 - 501
[7] EVALUATION OF A PORTABLE PROTHROMBIN TIME MONITOR FOR HOME-USE BY PATIENTS WHO REQUIRE LONG-TERM ORAL ANTICOAGULANT-THERAPY
ANDERSON, DR
HARRISON, L
HIRSH, J
[J]. ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (12) : 1441 - 1447
[8] Andrew Maureen, 1995, Blood, V86, p863A
[9] [Anonymous], 1994, Lancet, V343, P499
[10] [Anonymous], 1987, HEMATOL REV